Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8780358 | Gynecologic Oncology | 2018 | 11 Pages |
Abstract
Progression-free survival in White (A, C, E) or Black (B, D, F) endometrial cancer patients with versus without the copy number variant (CNV)-high subtype (A, B), the somatic copy number alterations (SCNA) cluster 4 subtype (C, D), or the transcript-based mitotic subtype (E, F). Survival distributions compared using log-rank testing. Bar chart displaying the proportion of patients with the more-aggressive copy number variant (CNV)-high subtype, the somatic copy number alterations (SCNA) cluster 4 subtype, or the transcript-based mitotic subtype (G). Fisher's exact testing was used to compare categorical variables. Venn diagram of the most significantly up-regulated transcripts in cell cycle signaling and in pathways in cancer in Black and/or in White endometrial cancer patients with mitotic versus non-mitotic subtypes with > 2-fold change elevation and a false discovery rate < 0.01 (H).263
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Elizabeth A. MD, LCDR, MC, USN, Chunqiao Tian, Guisong Wang, Christopher M. Tarney, Nicholas W. Bateman, Douglas A. Levine, Thomas P. Conrads, Chad A. Hamilton, George Larry Maxwell, Kathleen M. Darcy,